WHO COLLABORATING CENTRE FOR DRUG STATISTICS METHODOLOGY
To the users of the ATC/DDD system 26 November 2018
Dear all,
ATC/DDD alterations and new ATC/DDDs – valid from January 2019
Enclosed please find the lists of ATC and DDD alterations valid from January 2019. Lists of new ATC codes and new DDDs to be included in the 2019 edition of the ATC/DDD Index are also enclosed.
ATC alterations Only one ATC alteration is made. The ATC code for dimethyl fumarate is changed from N07XX09 to L04AX07 in order to cover both approved indications, i.e. multiple sclerosis and plaque psoriasis.
DDD alterations DDDs for several antibacterials for systemic use (J01) have been altered. In addition the DDD for aprepitant (A04AD12) have been altered from 95 mg (O,P) to 165 mg (O) and 150 mg (P). The new DDDs are based on the single dose treatment on day one.
Updated versions of the ATC/DDD Index and the Guidelines for ATC classification and DDD assignment will be distributed in January 2019. These publications are available in English and Spanish. Please find the order form on our website www.whocc.no.
If you need further information, please feel free to contact us ([email protected]).
For your information, the next course in the ATC/DDD methodology will be arranged in Oslo 13-14 June 2019. Please see the enclosed invitation. You will be able to make your registration from February.
Yours sincerely,
Irene Litleskare
Enclosures
Postal address: Office address: Telephone: + 47 21 07 81 60 P.O.Box 222 Skøyen Sandakerveien 24C, Bygg C N-0213 Oslo N-0473 Oslo E-mail: [email protected]
ALTERATIONS IN ATC CLASSIFICATION valid from January 2019 sorted according to previous ATC code
Previous ATC code ATC level name New ATC code
N07XX09 dimethyl fumarate L04AX07
WHO Collaborating Centre for Drug Statistics Methodology Oslo, November 2018 Other alterations in ATC classification, i.e. new levels (this list includes only new levels assigned in connection with an alteration), deleted levels and altered names of ATC levels valid from January 2019 sorted according to ATC code
ATC code Previous ATC level name New ATC level name or new ATC level A12BA30 combinations potassium (different salts in combination)
C09C Angiotensin II antagonists, plain Angiotensin II receptor blockers (ARBs), plain C09CA Angiotensin II antagonists, plain Angiotensin II receptor blockers (ARBs), plain C09D Angiotensin II antagonists, combinations Angiotensin II receptor blockers (ARBs), combinations C09DA Angiotensin II antagonists and diuretics Angiotensin II receptor blockers (ARBs) and diuretics C09DB Angiotensin II antagonists and calcium Angiotensin II receptor blockers (ARBs) channel blockers and calcium channel blockers C09DX Angiotensin II antagonists, other Angiotensin II receptor blockers (ARBs), combinations other combinations D08AK04 mercurochrome merbromin
L01XC16 dinutuximab dinutuximab beta L01XC29 ermekumab bermekimab
V09IX07 fluoromethylcholine (18F) fluorocholine (18F)
WHO Collaborating Centre for Drug Statistics Methodology Oslo, November 2018 ALTERATIONS IN DDDs valid from January 2019
ATC code ATC level name - Previous DDD New DDD
A04AD12 aprepitant 1) 95 mg P 150 mg P A04AD12 aprepitant 95 mg O 165 mg O H01BA01 vasopressin (argipressin) 4 U P 40 U P J01CA01 ampicillin 2 g P 6 g P J01CA04 amoxicillin 1 g O 1.5 g O J01CA04 amoxicillin 1 g P 3 g P J01CA17 temocillin 2 g P 4 g P amoxicillin and beta-lactamase J01CR02 1 g O 1.5 g O inhibitor J01DE01 cefepime 2 g P 4 g P J01DH02 meropenem 2 g P 3 g P J01MA02 ciprofloxacin 0.5 g P 0.8 g P J01XB01 colistin 3 MU P 9 MU P
1) Refers to fosaprepitant
WHO Collaborating Centre for Drug Statistics Methodology Oslo, November 2018
NEW ATC CODES valid from January 2019
ATC code ATC level name
A06AH05 naldemedine
A07XA06 crofelemer
A10BD23 metformin and ertugliflozin
A10BD24 sitagliptin and ertugliflozin
A10BD25 metformin, saxagliptin and dapagliflozin
A10BH52 gemigliptin and rosuvastatin
A10BK04 ertugliflozin
A10BK05 ipragliflozin
A16AX15 telotristat
B01AX07 caplacizumab
B02BX07 lusutrombopag
B02BX08 avatrombopag
B02BX09 fostamatinib
B03XA05 roxadustat
B06AC05 lanadelumab
C01CX09 angiotensin II
C02KX52 ambrisentan and tadalafil
C09DX05 valsartan and nebivolol
C09DX06 candesartan, amlodipine and hydrochlorothiazide
D04AX01 doxepin
D10AD06 trifarotene
D11AH06 crisaborole
D11AX25 hydrogen peroxide
G01AX17 dapivirine
G02BB02 vaginal ring with progestogen
G03AA17 medroxyprogesterone and estradiol
G03AB09 norgestimate and ethinylestradiol G03XX Other sex hormones and modulators of the genital system
G03XX01 prasterone
G04CX04 fexapotide
J01AA13 eravacycline
J01DD18 cefteram
J01DD64 cefpodoxime and beta-lactamase inhibitor
J01DH06 tebipenem pivoxil
J01DH52 meropenem and vaborbactam J01MA22 tosufloxacin J01MA23 delafloxacin
J04AM07 rifampicin, ethambutol and isoniazid
J04AM08 isoniazid, sulfamethoxazole, trimethoprim and pyridoxine
J05AG06 doravirine
J05AH03 peramivir
J05AP57 glecaprevir and pibrentasvir
J05AR23 atazanavir and ritonavir
J05AR24 lamivudine, tenofovir disoproxil and doravirine
J05AX17 enisamium iodide
J05AX18 letermovir
J05AX19 tilorone
J05AX21 pentanedioic acid imidazolyl ethanamide
J05AX23 ibalizumab
L01AD08 uramustine
L01BC09 floxuridine
L01XC31 avelumab
L01XC32 atezolizumab
L01XE44 lorlatinib
L01XE45 neratinib
L01XE46 encorafenib
L01XE47 dacomitinib
L01XE48 icotinib
L01XE50 abemaciclib L01XX58 epacadostat
L01XX59 enasidenib
L01XX60 talazoparib
L01XX61 copanlisib
L01XY01 cytarabine and daunorubicin
L02AE51 leuprorelin and bicalutamide
L02BB05 apalutamide
L04AA38 ozanimod
L04AA39 emapalumab
L04AA40 cladribine 1)
L04AC17 tildrakizumab
M05BB09 ibandronic acid and colecalciferol
N02CX08 galcanezumab
N03AX24 cannabidiol
N07XX12 patisiran
N07XX13 valbenazine
N07XX14 edaravone
P01CA03 fexinidazole
R03CC63 clenbuterol and ambroxol
S01EX06 omidenepag
S01XA26 riboflavin
V04CX01 indocyanine green
1) Oral formulations indicated for multiple sclerosis. Parenteral formulations are classified in L01BB04
WHO Collaborating Centre for Drug Statistics Methodology Oslo, November 2018
NEW DDDs valid from January 2019
ATC code ATC level name New DDD A04AD14 rolapitant 0.18 g O
A05AA01 chenodeoxycholic acid 1 g O
A06AH05 naldemedine 0.2 mg O
A07AA08 kanamycin 3 g O
A07AA10 colistin 9 MU O
A07DA06 eluxadoline 0.2 g O
A10AE54 insulin glargine and lixisenatide 40 U 1) P
A10BK04 ertugliflozin 10 mg O
A16AX15 telotristat 0.75 g O
B02BX06 emicizumab 15 mg P
C01CA27 droxidopa 1 g O
D11AH05 dupilumab 21.4 mg P
G02AD06 misoprostol 0.2 mg O
G03CA03 estradiol 1.53 mg TD spray
G03GA10 follitropin delta 12 mcg P
G04BD13 desfesoterodine 3.5 mg O
H03AA05 thyroid gland preparations 0.1 g O
J01DB11 cefroxadine 2.1 g O
J01DD18 cefteram 0.4 g O
J01DD63 ceftriaxone and beta-lactamase inhibitor 2 g 2) P
J01DH06 tebipenem pivoxil 0.56 g O
J01DI03 faropenem 0.75 g O
J01FA03 midecamycin 1.2 g O
J01MA07 lomefloxacin 0.4 g O
J01MA15 gemifloxacin 0.32 g O
J01MA19 garenoxacin 0.4 g O J01MA22 tosufloxacin 0.45 g O
J01MA23 delafloxacin 0.9 g O
J01MA23 delafloxacin 0.6 g P
J04AK06 delamanid 0.2 g O
J05AC02 rimantadine 0.2 g O
J05AR23 atazanavir and ritonavir 0.3 g 3) O
J05AX17 enisamium iodide 1.5 g O
J05AX18 letermovir 0.48 g O,P
J05AX19 tilorone 0.125 g O
J05AX21 pentanedioic acid imidazolyl ethanamide 90 mg O
L04AA36 ocrelizumab 3.29 mg P
L04AA37 baricitinib 4 mg O
L04AA40 cladribine 0.34 mg O
L04AC14 sarilumab 14.3 mg P
L04AC16 guselkumab 1.79 mg P
M09AX07 nusinersen 0.1 mg P
N05AX15 cariprazine 3 mg O
P01AB07 secnidazole 2 g O
P01BD51 pyrimethamine, combinations 75 mg 4) P
P01BE02 artemether 0.28 g R
P01BE03 artesunate 0.28 g R
R03DA12 mepyramine theophyllinacetate 0.6 g O
R03DX08 reslizumab 7.1 mg P
R03DX10 benralizumab 0.54 mg P
V03AE09 patiromer calcium 8.4 g O
1) refers to insulin glargine 2) refers to ceftriaxone 3) refers to atazanavir 4) refers to pyrimethamine
WHO Collaborating Centre for Drug Statistics Methodology Oslo, November 2018